Clinical Documents

To edit the draft, click on the text box below.

×

Draft a comprehensive differential diagnosis for acute substernal chest pain in a 45-year-old male with hypertension and hyperlipidemia, diaphoresis, exertional onset, and normal initial ECG/troponin; include life-threatening causes first, key distinguishing features, and immediate diagnostic next steps.

Draft a detailed differential diagnosis for new-onset unilateral throbbing headache with visual aura and brief monocular vision loss in a 32-year-old female on oral contraceptives; include red-flag symptoms, stroke/TIA considerations, and recommended initial workup.

Draft an assessment and plan for stage-2 hypertension (BP 162/98) in an obese 52-year-old with suspected obstructive sleep apnea; include ASCVD risk estimate, lifestyle prescriptions, first-line pharmacotherapy with drug/dose/targets, baseline labs/monitoring, and 4–6 week follow-up.

Draft an assessment and plan for type 2 diabetes follow-up with A1c 9.2% on metformin 1,000 mg BID and eGFR 65; compare adding a GLP-1 receptor agonist vs an SGLT2 inhibitor, address weight loss goals, hypoglycemia education, vaccinations, and micro/macrovascular screening.

Draft a history and physical for a patient presenting with chest pain, including HPI using OLDCARTS, pertinent ROS, PMH/meds/allergies, FH/SH, focused cardiac/pulmonary exam, initial labs and imaging orders, prioritized differential, HEART score risk stratification, and early management.

Draft a history and physical for a new patient with progressive exertional dyspnea, orthopnea, and bilateral leg edema; include differential (heart failure, COPD, PE, anemia, renal disease), targeted exam maneuvers, and first-line diagnostics and management.

Draft a progress note for COPD follow-up two weeks after an acute exacerbation treated with prednisone and antibiotics; include symptom trajectory, CAT score (if available), inhaler technique/adherence, oxygen needs, spirometry plan, smoking cessation counseling, and return precautions.

Draft a progress note for post-operative day 2 after total knee arthroplasty; include pain control strategy, DVT prophylaxis, PT/OT milestones, wound status, bowel/urinary function, labs/vitals review, complications screening, and discharge readiness.

Draft a discharge summary for community-acquired pneumonia admission; include admission/discharge dates, presenting symptoms, radiology/labs, pathogen if identified, inpatient therapies and response, discharge medications with durations, pending tests, follow-up appointments, and return precautions.

Draft a discharge summary for myocardial infarction managed with PCI and drug-eluting stent placement; include cath findings, complications, inpatient course, discharge medications (DAPT, statin, beta-blocker, ACEi/ARB), cardiac rehab referral, and follow-up plan.

Draft discharge instructions for a patient hospitalized with acute decompensated heart failure; include daily weights, sodium and fluid restriction amounts, medication list with dosing, signs of worsening heart failure, follow-up appointments, and lab monitoring plan.

Draft discharge instructions for an asthma exacerbation; include controller and reliever regimen, steroid taper schedule, spacer technique, trigger avoidance, a written asthma action plan, return precautions, and follow-up timing.

Draft a patient handout on managing high blood pressure in plain language; explain what BP numbers mean, key lifestyle steps (DASH diet, sodium limits, alcohol moderation), home BP monitoring instructions, medication adherence tips, and when to call the doctor.

Draft a patient handout for type 2 diabetes education in plain language; cover A1c goals, the plate method, physical activity targets, self-monitoring of blood glucose, hypoglycemia signs and the 15-15 rule, foot care basics, and a vaccination checklist.

Draft a summary of the latest CDC and WHO guidelines for managing community-acquired pneumonia in adults, including empiric antibiotic choices, duration of therapy, and follow-up recommendations.

Draft a plain-language overview of the ADA and AACE guidelines for diabetes management, focusing on A1c goals, weight management, and the use of GLP-1 receptor agonists and SGLT2 inhibitors.

Draft a summary of the 2024 USPSTF breast cancer screening recommendations, including updated screening intervals, risk-based approaches, and the role of MRI for high-risk patients.

Draft a concise summary of NCCN guidelines for melanoma management, including staging, surgical margins, adjuvant therapy, and checkpoint inhibitor recommendations.

Draft treatment alternatives for community-acquired MRSA skin infections in patients allergic to sulfa drugs; include oral and IV options, dosing, and duration.

Draft treatment alternatives for patients with type 2 diabetes who are unable to tolerate GLP-1 receptor agonists due to nausea; include medication substitutions and lifestyle recommendations.

Draft a summary of options for treating refractory depression, comparing ketamine infusions, transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT).

Draft treatment options for advanced prostate cancer, including hormonal therapy, radiopharmaceuticals, and novel androgen receptor pathway inhibitors.

Draft a summary of recent research on mRNA vaccine technology beyond COVID-19, including applications in oncology and autoimmune disease prevention.

Draft an easy-to-understand overview of long COVID research, summarizing major symptoms, hypothesized mechanisms, and emerging treatment approaches.

Draft a summary of current research on Alzheimer’s disease biomarkers, including amyloid and tau imaging, and discuss how they influence diagnosis and trial design.

Draft an explanation of the interaction between warfarin and antibiotics such as ciprofloxacin or TMP-SMX, including INR effects and management recommendations.

Draft a summary evaluating drug interactions for patients taking Paxlovid and common cardiovascular drugs; include mechanism and recommended dose adjustments.

Draft a summary of the common and serious side effects of semaglutide, including GI intolerance, gallbladder disease, and thyroid-related warnings.

Draft an overview of potential side effects associated with long-term corticosteroid use, including osteoporosis, glucose intolerance, and adrenal suppression.

Draft a summary of essential lab tests to order in suspected acute pancreatitis, including amylase, lipase, liver enzymes, and metabolic panels, with interpretation guidance.

Draft laboratory workup recommendations for suspected hypothyroidism, including TSH, free T4, thyroid antibodies, and when to consider secondary causes.

Draft an explanation of which labs should be monitored in patients receiving methotrexate therapy, including CBC, LFTs, renal function, and frequency of monitoring.

why choose us

Edit Geo

×

300×250 Ad Slot

Research Article: The relationship between pan immune inflammatory index (PIV) and 28 day mortality in patients with severe urinary sepsis: a retrospective study of a multinational dual cohort study

Date Published: 2026-07-10

Abstract:
Urosepsis is a critical condition originating from urinary tract infections, characterized by rapid progression and high mortality. The Pan-immune-inflammation Value (PIV), a novel composite index reflecting integrated immune and inflammatory status, has shown prognostic value in various critically ill and septic populations. However, its independent prognostic value in urosepsis remains inadequately explored. This study therefore aims to systematically evaluate the ability of PIV to predict 28-day adverse outcomes in patients with urosepsis. This study employed a retrospective dual-cohort design. The internal training cohort comprised adult ICU patients with urosepsis from the MIMIC-IV database, while the external validation cohort was derived from the electronic medical record system of Anshun Municipal People’s Hospital. To investigate the association between the PIV and short-term adverse outcomes in urosepsis patients, we utilized a range of statistical methods, including multivariable Cox regression, restricted cubic spline (RCS) analysis, subgroup analysis, and Kaplan-Meier survival curves. To develop a parsimonious predictive model, the internal cohort was randomly split into training and testing sets at a 7:3 ratio. Within the training set, an ensemble machine learning strategy—incorporating the Boruta algorithm, LASSO-Cox regression, random forest (RF), gradient boosting (GBDT), and support vector machine (SVM)—was applied to identify key predictive variables from serological tests, comorbidities, demographic characteristics, and vital signs. Based on the selected features, prognostic models were constructed using multivariable Cox regression in the training, testing, and external validation sets, respectively. The discriminatory power of these models against traditional disease severity scores was assessed using receiver operating characteristic (ROC) curves, with the area under the curve (AUC) quantifying predictive performance. A total of 1,686 patients with severe urosepsis were included in this study. In the fully adjusted model, both continuous PIV and PIV quartiles were independently associated with 28-day adverse outcomes. For 28-day ICU mortality, each unit increase in continuous PIV was associated with a 76.4% higher risk (HR 1.764, 95% CI 1.340–2.323, p < 0.001); compared with the lowest quartile (Q1), the highest quartile (Q4) showed a significantly increased risk of 84.3% (HR 1.843, 95% CI 1.186–2.846, p = 0.007). For 28-day in-hospital mortality, the HR for continuous PIV was 1.639 (95% CI 1.214–2.214, p < 0.001), and the HR for Q4 was 1.789 (95% CI 1.110–2.885, p = 0.039). In the external validation cohort, the predictive value of PIV for 28-day ICU mortality remained consistent and was even more pronounced (continuous PIV: HR 1.79, 95% CI 1.21–2.64, p = 0.004). Restricted cubic spline analysis further confirmed a significant positive dose-response relationship between PIV and mortality (overall p < 0.001). The risk prediction model based on PIV demonstrated good discriminative ability, with areas under the receiver operating characteristic curve of 0.71, 0.73, and 0.76 in the training, internal testing, and external validation sets, respectively, all of which were higher than those of traditional severity scores (e.g., SOFA, APACHE II). This study confirms PIV as an independent predictor of 28-day mortality risk in patients with urosepsis across two cohorts. The prediction model incorporating PIV and four other clinical variables exhibited good discrimination and calibration, with prognostic performance superior to that of traditional disease severity scores. Future prospective, multicenter studies involving diverse geographic and ethnic populations are needed to further validate the generalizability of this model, thereby facilitating precise risk stratification for patients with urosepsis.

Introduction:
Urosepsis is a critical condition originating from urinary tract infections, characterized by rapid progression and high mortality. The Pan-immune-inflammation Value (PIV), a novel composite index reflecting integrated immune and inflammatory status, has shown prognostic value in various critically ill and septic populations. However, its independent prognostic value in urosepsis remains inadequately explored. This study therefore aims to systematically evaluate the ability of PIV to predict 28-day adverse…

Read more

300×250 Ad Slot

×
Chat & Ask Questions Career Openings Medical Doctors Check on Drug
Interactions Latest Health News
by WebHealthNetwork Get CME Credits Latest Clinical Trials Latest Research Articles Clinical Documents Update Profile

News

Chat

HCP Tools

Careers

Update Profile